-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $48

Benzinga·11/16/2026 14:14:30
Listen to the news
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $48.